Modified Oncolytic Herpesviruses for Gene Therapy of Cancer

Shanthi Sivendran, Joe Goldufsky, Howard Kaufman, Yvonne Saenger

Research output: Chapter in Book/Report/Conference proceedingChapter


Herpes simplex viruses (HSV) possess unique functions as both oncolytic vectors and vaccines capable of initiating an innate host antitumor immune response and have been developed for the gene therapy of cancer. Modifications of viral genes encoding pathogenicity and immunogenicity proteins and insertion of eukaryotic immune enhancing genes have resulted in viral strains with selective tumor oncolytic and potent immunization potential with an acceptable safety profile and no neurotoxicity. Several modified HSV vectors are currently in clinical trials, with the most experience in the treatment of advanced melanoma. In this chapter, we discuss the basic biology of HSV, describe the origin of individual oncolytic HSV strains in clinical use, and present the results of clinical trials for melanoma and other human cancers.

Original languageEnglish (US)
Title of host publicationGene Therapy of Cancer
Subtitle of host publicationTranslational Approaches from Preclinical Studies to Clinical Implementation: Third Edition
PublisherElsevier Inc.
Number of pages11
ISBN (Print)9780123942951
StatePublished - Aug 2013
Externally publishedYes


  • Advanced cancer
  • Herpes simplex virus
  • Immunotherapy
  • Oncolysis
  • Vaccin

ASJC Scopus subject areas

  • Dentistry(all)
  • Medicine(all)


Dive into the research topics of 'Modified Oncolytic Herpesviruses for Gene Therapy of Cancer'. Together they form a unique fingerprint.

Cite this